A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade



Summary

This research presents a novel CD27 agonistic antibody engineered for enhanced activity. By promoting hexamerization (clustering), the antibody robustly activates CD27 on T cells, amplifying their effector functions. Simultaneously, the antibody’s Fc region is silenced to minimize unwanted side effects. Importantly, the hexamerization-enhanced antibody demonstrates significant anti-tumor activity as a single agent. Furthermore, it synergizes with PD-1 blockade, a common cancer immunotherapy, to further augment T-cell responses and improve therapeutic outcomes. This antibody represents a promising strategy to harness CD27 signaling for cancer immunotherapy, both alone and in combination with existing treatments.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!